Questioning the economic evaluation of omalizumab

[...]there is only a moderate (at best) association between pulmonary function and quality of life and symptom experience in asthmatic patients. [...]the current model might underestimate the effectiveness of omalizumab on quality-of-life outcomes. Again, this assumed relationship between pulmonary function and health preferences seems likely to underestimate the effect of omalizumab on quality-of-life outcomes in asthmatic patients. Because adequately quantifying the "effectiveness" of a treatment is essential for a cost-effectiveness analysis, the methods used by the authors seem unlikely to capture the complete benefits associated with omalizumab therapy.